Logo

HAE

Haemonetics Corporation

HAE

Haemonetics Corporation • NYSE
$81.35 ▲ 0.74% (+0.60)
Market Cap $3.97 B
52w High $88.31
52w Low $47.32
Dividend Yield 0%
P/E 23.79
Volume 303.21K
Outstanding Shares 48.79M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2026 $327.315M ▲ $136.253M ▼ $38.684M ▲ 11.819% ▲ $0.81 ▲ $86.752M ▼
Q1-2026 $321.394M ▼ $137.987M ▲ $34.031M ▼ 10.589% ▼ $0.71 ▼ $93.696M ▼
Q4-2025 $330.599M ▼ $121.715M ▼ $57.981M ▲ 17.538% ▲ $1.17 ▲ $99.543M ▲
Q3-2025 $348.542M ▲ $140.886M ▲ $37.494M ▲ 10.757% ▲ $0.75 ▲ $95.136M ▲
Q2-2025 $345.511M $139.505M $33.831M 9.792% $0.66 $88.979M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2026 $296.426M ▲ $2.442B ▼ $1.593B ▲ $849.173M ▼
Q1-2026 $292.898M ▼ $2.462B ▲ $1.58B ▼ $882.3M ▲
Q4-2025 $306.763M ▼ $2.451B ▼ $1.63B ▲ $820.836M ▼
Q3-2025 $320.846M ▲ $2.531B ▲ $1.624B ▼ $906.86M ▲
Q2-2025 $299.283M $2.525B $1.646B $878.851M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2026 $38.684M ▲ $111.321M ▲ $-30.468M ▲ $-76.552M ▼ $3.528M ▲ $106.305M ▲
Q1-2026 $34.031M ▼ $17.395M ▼ $-33M ▼ $-2.442M ▲ $-13.865M ▲ $13.641M ▼
Q4-2025 $57.981M ▲ $116.557M ▲ $18.04M ▲ $-151.45M ▼ $-14.083M ▼ $100.914M ▲
Q3-2025 $37.494M ▲ $43.766M ▼ $-17.371M ▲ $1.38M ▲ $21.563M ▲ $35.22M ▼
Q2-2025 $33.831M $48.823M $-23.367M $-74.804M $-45.146M $39.39M

Revenue by Products

Product Q3-2025Q4-2025Q1-2026Q2-2026
Apheresis Blood Center
Apheresis Blood Center
 $0 ▲$0 ▲$0 ▲$60.00M ▲
Blood Center
Blood Center
 $70.00M ▲$50.00M ▼$50.00M ▲$60.00M ▲
Hemostasis Management Hospital
Hemostasis Management Hospital
 $0 ▲$0 ▲$0 ▲$90.00M ▲
Hospital
Hospital
 $140.00M ▲$150.00M ▲$140.00M ▼$150.00M ▲
Interventional Technologies Hospital
Interventional Technologies Hospital
 $0 ▲$0 ▲$0 ▲$60.00M ▲
Plasma
Plasma
 $130.00M ▲$130.00M ▲$130.00M ▲$130.00M ▲
Whole Blood Blood Center
Whole Blood Blood Center
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Haemonetics has grown its sales steadily over the past five years, showing that demand for its products is expanding across plasma, hospital, and blood center markets. Profitability has improved faster than revenue, suggesting better pricing, mix, and cost control. Operating margins have widened meaningfully, and earnings per share have climbed over time after a weaker period a few years ago. There is still some history of earnings volatility, but the recent trend is toward more consistent and higher profitability.

Balance Sheet

Balance Sheet The balance sheet shows a business that has been adding assets and scale, but also taking on more debt to fund growth and acquisitions. Cash levels move around year to year but remain reasonable relative to the size of the company. Equity has been broadly stable over time, which means leverage has increased as borrowing has grown. The company now relies more on debt than it did a few years ago, which can enhance returns but also raises sensitivity to interest costs and economic slowdowns.

Cash Flow

Cash Flow Haemonetics consistently generates cash from its operations, and this has been sufficient to cover its investment spending and still leave room for positive free cash flow. Operating cash flow peaked a couple of years ago and has since leveled off, which may reflect working capital needs or integration of new businesses. Capital spending has risen but remains measured, indicating ongoing investment in equipment, technology, and capacity without straining the company’s finances. Overall, cash generation supports both reinvestment and the servicing of higher debt levels, though there is less cushion than if cash flow were still climbing.

Competitive Edge

Competitive Edge The company holds a very strong position in the plasma collection market, where it is the dominant supplier of automated systems and related disposables. Its “razor-and-blade” model, with installed devices tied to recurring sales of single-use kits, creates stable, repeat business and makes customers less likely to switch. Deep integration between its hardware and proprietary software increases switching costs further. In hospitals and diagnostics, Haemonetics competes with large global players, but its specialized products and long-standing customer relationships give it a defensible niche. Key risks include reliance on a concentrated plasma market, potential pricing pressure, and regulatory or reimbursement changes in healthcare.

Innovation and R&D

Innovation and R&D Innovation is central to Haemonetics’ strategy. The company has enhanced its core plasma systems with personalized collection technology and tightly integrated donor management software, improving yields and center efficiency. In hospitals, it has advanced offerings in blood salvage and coagulation testing, moving from older platforms to more automated, point-of-care systems. Recent acquisitions in interventional cardiology and electrophysiology broaden its reach into faster-growing procedure areas and add new technical capabilities. A sizable product pipeline and ongoing upgrades to existing platforms suggest that R&D spending is being used not only to defend current positions but also to open new avenues for growth, though integration and execution will be important to realize this potential.

Summary

Overall, Haemonetics combines steady revenue growth, expanding margins, and consistent free cash flow with a strong competitive foothold in a specialized corner of medical technology. Its leadership in plasma collection, recurring consumables model, and integrated software ecosystem underpin a durable business profile. At the same time, the company has increased its use of debt and is leaning into acquisitions to drive future growth, which adds financial and integration risk. Continued success will depend on maintaining its technology lead, managing regulatory and reimbursement exposure, and converting its product pipeline and new business lines into sustained, profitable expansion.

NEWS

November 14, 2025 · 7:00 AM UTC

DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)

Read more

November 6, 2025 · 8:00 AM UTC

BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)

Read more

November 6, 2025 · 8:00 AM UTC

Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart

Read more

November 6, 2025 · 6:00 AM UTC

Haemonetics Corporation Announces Second Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

Read more

October 23, 2025 · 7:00 AM UTC

BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

Read more